VIENNA—Because harnessing the immune system is now proven as a way of managing breast cancer, clinicians should consider the role of tumor infiltrating lymphocytes, according to Giuseppe Curigliano MD PhD, Director of the Early Drug Development for Innovative Therapies Division at the European Institute of Oncology, Milan—who presented an update of their role in mediating immune pathways in cancer at the St Gallen Breast Cancer Conference. He gave Oncology Times reporter Sarah Maxwell his insights into how the “immunome” could be used as a target.
You may also like...
Can these Women with Breast Cancer Avoid Chemotherapy? 24 Aug, 2016 The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer. 19 Nov, 2013 Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015 For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival 28 Sep, 2009
- Previous story International Research and Consensus Needed to Interpret Breast Cancer Genomics Data
- Next story BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014